Opportunities and limitations of synthetic media in the production of content
Media: Theory and Practice · 30.06.2025 · 18
DOI: 10.65324/mtp018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Media: Theory and Practice, online erschienen am 30.06.2025. Verfasst von Matvey Melnikov. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The 21st century is characterized by the continued rapid development of digital technologies. The media industry is the fastest growing sector of modern business and is most subject to structural changes, evolution of media and communication methods. One of these changes is the emergence of synthetic media and the introduction of neural networks and artificial intelligence into the communication process. These technologies trigger a new round of media space development, as they provide an opportunity to generate new types of content and have a qualitative impact on the industry. The possibilities of synthetic media in the future may open completely new vectors of industry development and generate new formats of textual and audiovisual content due to the “out-of-the-box thinking” of artificial intelligence and neural networks. Synthetic media have the potential for development and are at the stage of initial formation, but despite this, they are already capable of generating content not only indistinguishable from human-generated content, but in some cases even superior to it.
Zitieren
APA
Melnikov, M. (2025). Opportunities and limitations of synthetic media in the production of content. Media: Theory and Practice, 18. https://doi.org/10.65324/mtp018
Vancouver
Melnikov M. Opportunities and limitations of synthetic media in the production of content. Media: Theory and Practice. 2025:18. doi:10.65324/mtp018
BibTeX
@article{Melnikov2025,
author = {Melnikov, Matvey},
title = {Opportunities and limitations of synthetic media in the production of content},
journal = {Media: Theory and Practice},
year = {2025},
pages = {18},
doi = {10.65324/mtp018}
}
EUVIMED